Jiangsu Hengrui Medicine Co., Ltd
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-11-06
- Last Posted Date
- 2018-11-06
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03732508
- Locations
- 🇨🇳
Cancer Institute and Hospital,Chinese Academy of Medical Science, Beijing, Beijing, China
Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2018-10-26
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 128
- Registration Number
- NCT03722186
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 99
- Registration Number
- NCT03711279
- Locations
- 🇨🇳
Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, Shanghai, China
A Safety Study of Multiple Subcutaneous (s.c.) Injections of SHR-1314 in Adults With Moderate-to-severe Plaque Psoriasis
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT03710681
- Locations
- 🇨🇳
Huanshan Hospital , Shanghai Fudan University, Shanghai, China
Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
- Conditions
- Interventions
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2022-04-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 462
- Registration Number
- NCT03711305
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Jilin Cancer Hospital, Jilin, Changchun, China
SHR-1701 in Metastatic or Locally Advanced Solid Tumors
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 206
- Registration Number
- NCT03710265
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 263
- Registration Number
- NCT03707509
- Locations
- 🇨🇳
Cancer Center of Sun-Yat Sen University (CCSYSU), Guangzhou, Guangdong, China
Safety, Tolerability and PK of SHR1314 in axSpA
- First Posted Date
- 2018-10-12
- Last Posted Date
- 2021-01-13
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT03704428
- Locations
- 🇨🇳
Jianwen Chen, Shanghai, China
Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 596
- Registration Number
- NCT03691090
- Locations
- 🇨🇳
Cancer Center of Sun-Yat Sen University (CCSYSU), Guangzhou, Guangdong, China
A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC
- Conditions
- Interventions
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2021-03-15
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 390
- Registration Number
- NCT03668496
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Anhui Chest Hospital, Hefei, Anhui, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China